1. Faruqi & Faruqi is investigating claims against Pacira BioSciences, Inc. 2. Pacira's '495 patent was invalidated by the New Jersey District Court. 3. Post-announcement, Pacira's stock fell over 47%, damaging investors significantly. 4. Investors are encouraged to contact the firm for legal recourse by March 14. 5. The court's ruling surprised the market, impacting stock price drastically.
The invalidation of the key '495 patent substantially weakens Pacira's market position, similar to past instances like the decline seen in companies post FDA rejections or patent invalidations, which often led to dramatic drops in stock price.
The significant patent invalidation and ongoing class action are critical legal issues that could drastically affect future revenue and investor sentiment.
The immediate reaction of over 47% decline indicates rapid market response, typical in legal and patent issues, though longer-term recovery could occur depending on subsequent developments in litigation or business strategy.